



Atty. Dkt. No. 071949-5408

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: VALKIRS et al.

Title: DIAGNOSTIC MARKERS OF
STROKE AND CEREBRAL
INJURY AND METHODS OF
USE THEREOF

Appl. No.: 10/714,078

Filing Date: 11/14/2003

Examiner:

Art Unit:

| |
|--|
| <p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.</p> <p align="center"><u>DIANE GARCIA</u> (Printed Name)</p> <p align="center"><u>Diane Garcia</u> (Signature)</p> <p align="center"><u>1-8-2004</u> (Date of Deposit)</p> |
|--|

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in corresponding application Serial Nos. 10/371,149, filed 02/20/2003 and 10/225,082, filed 08/20/2002. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent applications.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



Atty. Dkt. No. 071949-5408

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date

1/8/04

By

Barry Wilson

FOLEY & LARDNER

Customer Number: 30542


Telephone: (858) 847-6722

Facsimile: (858) 792-6773

Barry S. Wilson

Attorney for Applicant

Registration No. 39,431



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/ 371,149 |
| | | Filing Date | 02/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 1 | of | 1 |
| | | Attorney Docket Number | 071949-5406 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | A1 | 6,235,489 B1 | | Jackowski et al. | May 22, 2001 | |
| | A2 | 6,268,223 B1 | | Cornell-Bell et al. | July 31, 2001 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | A3 | WO | 00/52476 A1 | | Skye Pharmatech Incorporated | Sept. 8, 2000 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A4 | Feinberg et al., "Guidelines for the Management of Transient Ischemic Attacks." Stroke, 25(6): 1320-1335, June 1994. | |
| | A5 | Herrmann et al., "Release of Glial tissue-specific proteins after acute stroke: A comparison analysis of serum concentrations of protein S-100B and Glial fibrillary acidic protein." Stroke, 31:2670-2677, 2000. | |
| | A6 | Napoli et al., "C-reactive protein in ischemic stroke: An independent prognostic factor." Stroke, 32:917-924, 2001. | |
| | A7 | Strand et al., "Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke." Stroke, 15(1): 138-144, 1994. | |
| | A8 | Hirashima et al., "Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage." Neurochemical Research, 22(10): 1249-1255, 1997. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/1371,149 |
| | | Filing Date | 02/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 2 | of | 1 |
| | | Attorney Docket Number | 071949-5406 |


| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁸ |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|-------|---|----|----|
| Sheet | 1 | of | 21 |
|-------|---|----|----|

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|----------------------|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| | A1 | 5,114,923 | | Seilhamer et al. | May 19, 1992 | |
| | A2 | 5,480,792 | | Buecler et al. | Jan. 2, 1996 | |
| | A3 | 5,525,524 | | Buechler et al. | Jun. 11, 1996 | |
| | A4 | 5,631,171 | | Sandstrom et al. | May 20, 1997 | |
| | A5 | 5,679,526 | | Buechler et al. | Oct. 21, 1997 | |
| | A6 | 5,824,799 | | Buechler et al. | Oct. 20, 1998 | |
| | A7 | 5,851,776 | | Valkirs | Dec. 22, 1998 | |
| | A8 | 5,885,527 | | Buechler | Mar. 23, 1999 | |
| | A9 | 5,922,615 | | Nowakowski et al. | Jul. 13, 1999 | |
| | A10 | 5,939,272 | | Buechler et al. | Aug. 17, 1999 | |
| | A11 | 5,947,124 | | Buechler et al. | Sep. 7, 1999 | |
| | A12 | 5,955,377 | | Maul et al. | Sep. 21, 1999 | |
| | A13 | 5,985,579 | | Buechler et al. | Nov. 16, 1999 | |
| | A14 | 6,019,944 | | Buechler | Feb. 1, 2000 | |
| | A15 | 6,057,098 | | Buechler et al. | May 2, 2000 | |
| | A16 | 6,113,855 | | Buechler et al. | Sep. 5, 2000 | |
| | A17 | 6,143,576 | | Buechler | Nov. 7, 2000 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

[illegible]

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A19 | Aggarwal et al., "Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents," JIMA, 93:331-332, 1995. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|---|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 2 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A20 | Akiyama et al., "Changes in serum concentrations of matrix metalloproteins, tissue inhibitors of metalloproteinases and Type IV collagen in patients with various types of glomerulonephritis," Res. Commun. In Mol. Path. and Pharm., 95(2): 115-128, 1997. | |
| | A21 | Albrecht et al., "Detection of circulating tissue factor and factor VII in a normal population," Thrombosis and Haemostasis, 75(5): 772-7, 1996. | |
| | A22 | Albrechtsen and Bock, "Quantification of glial fibrillary acidic protein (GFAP) in human body fluids by means of ELISA employing a monoclonal antibody." Journal of Neuroimmunology, 8:301-309, 1985. | |
| | A23 | Austgulen et al., "Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia," Eur. J. Obstet. Gynecol. Reprod. Biol., 71:53-58, 1997. | |
| | A24 | Banks et al., "Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies," Br. J. Cancer, 68:122-124, 1993. | |
| | A25 | Bates et al., "Neurotrophin-3 promotes cell death induced in cerebral ischemia, oxygen-glucose deprivation, and oxidative stress: possible involvement of oxygen free radicals," Neurobiology of Disease, :24-37, 2002. | |
| | A26 | Benamer et al., "Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris," Am. J. Cardiol., 82:845-850, 1998. | |
| | A27 | Berendes et al., "Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage," Lancet, 349:245-249, 1997. | |
| | A28 | Bialik et al., "Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53," J.Clin.Invest., 100(6): 1363-1372, 1997. | |
| | A29 | Biasucci et al., "Elevated levels of interleukin-6 in unstable angina," Circulation, 94:874-877, 1996. | |
| | A30 | Biasucci et al., "Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction," Am. J. of Cardiol., 77:85-87, 1996. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A31 | Biasucci et al., "Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events," Circulation, 99:2079-2084, 1999. | |
| | A32 | Bitsch et al., "A longitudinal prospective study of soluble adhesion molecules in acute stroke," Stroke, 29:2129-2135, 1998. | |
| | A33 | Blankaert et al., "Constitutive release of metalloproteinase-9 (92-kd Type IV collagenase) by Kaposi's sarcoma cells," J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 18:203-209, 1998. | |
| | A34 | Blann et al., "Soluble intercellular adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke," Blood Coagul. Fibrinolysis, 10:277-284, 1999. | |
| | A35 | Bollensen et al., "Adenylate kinase enzyme activity in cases of brain infarction," Acta Neurol. Scand., 79:53-58, 1989. | |
| | A36 | Bonfrer et al., "The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma," Brit. Jour. Of Cancer, 77(12): 2210-2214, 1998. | |
| | A37 | Bonow, "New insights into the cardiac natriuretic peptides," Circulation, 93:1946-1950, 1996. | |
| | A38 | Bossink et al., "Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis," Blood, 86(10): 3841-3847, 1995. | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 4 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A39 | Caligiuri et al., "Immune system activation follows inflammation in unstable angina: pathogenetic implications," J.Am. Coll. Cardiol., 32:1295-1304, 1998. | |
| | A40 | Carlstedt et al., "Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease," Journal of Internal Medicine, 242:361-365, 1997. | |
| | A41 | Carter et al., "Platelet GP IIIa P1A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke," Arterioscler Thromb. Vasc. 18:1124-1131, 1998. | |
| | A42 | Carter et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature, 344:633-638, 1990. | |
| | A43 | Catto et al., "von Willebrand factor and factor VIII: C in acute cerebrovascular disease," Thromb. Haemost., 77:1104-8, 1997. | |
| | A44 | Curzen et al., "Can C reactive protein or troponins T and I predict outcome in patients with intractable unstable angina?" Heart, 80:23-27, 1998. | |
| | A45 | Dangas et al., "Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease," Am. J. Cardiol., 83:583-585, 1999. | |
| | A46 | Davie et al., "The coagulation cascade: initiation, maintenance and regulation," Biochemistry, 30(43): 10363-10370, 1991. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|---|----------------|
| | A47 | DeRose et al., "Circulating adhesion molecules in cystic fibrosis," Am. J. Respir. Crit. Care Med., 157: 1234-1239, 1998. | |
| | A48 | Eisenberg et al., "Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism," Proc. Nat. Acad. Sci. USA, 88: 5232-5236, 1991. | |
| | A49 | Emsley et al., "Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib," Journal of Biological Chemistry, 273(17): 10396-10401, 1998. | |
| | A50 | Endo et al., "Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer," Anticancer Research, 17:2253-2258, 1997. | |
| | A51 | Estrada et al., "High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke," Am. J. of Hypertension, 7(12): 1085-1089, 1994. | |
| | A52 | Fassbender et al., "Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease," Journal of the Neurological Sciences, 122:135-139, 1994. | |
| | A53 | Feinberg et al., "Hemostatic markers in acute ischemic stroke," Stroke, 27:1296-1300, 1996. | |
| | A54 | Fernandes-Alnemri et al., "CPP32, a novel human apoptotic protein with homology to <i>Caenorhabditis elegans</i> cell death protein Ced-3 and mammalian interleukin-1 β -converting enzyme," Journal of Biological Chemistry, 269(49): 30761-30764, 1994. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington D.C. 20231



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A55 | Fisher et al., "Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1 α in alcoholic liver disease," Gut, 45(3): 416-420, 1999. | |
| | A56 | Fon et al., "Hemostatic markers in acute transient ischemic attacks," Stroke, 25(2): 282-286, 1994. | |
| | A57 | Fujii et al., "Hemostasis in spontaneous subarachnoid hemorrhage," Neurosurgery, 37(2): 226-234, 1995. | |
| | A58 | Fujii et al., "Serial changes of hemostasis in aneurysmal subarachnoid hemorrhage with special reference to delayed ischemic neurological deficits," J.Neurosurg., 86:594-602, 1997. | |
| | A59 | Fujii et al., "Hemostasis in spontaneous subarachnoid hemorrhage." Neurosurgery, 37(2): 226-234, 1995. | |
| | A60 | Gabay et al., "Interleukin-1 receptor antagonist (IL-1Ra) is an acute-phase protein," J.Clin. Invest., 99(12): 2930-2940, 1997. | |
| | A61 | George et al., "Evidence for altered hepatic matrix degradation in genetic haemochromatosis," Gut, 42: 715-720, 1998. | |
| | A62 | Gohji et al., "Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma," Circulation, 99:608-613, 1999. | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet 7 of 21 | Attorney Docket Number | 071949-5404 | |


| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A63 | Goto et al., "Enhanced shear-induced platelet aggregation in acute myocardial infarction," Circulation, 99:608-613, 1999. | |
| | A64 | Guimaraes et al., "Potent constrictor actions of endothelin-1, endothelin-2, and endothelin-3 in rat isolated portal vein," Hypertension, 19(suppl. II): II79-II86, 1992. | |
| | A65 | Hanley and McNeil, "The meaning and use of the area under a receiver operating characteristic (ROC) curve," Radiology, 143:29-36, 1982. | |
| | A66 | Hasegawa et al., "Increased levels of calbindin-D in serum and urine from patients treated by extracorporeal shock wave lithotripsy," Journal of Urology, 149:1414-1418, 1993. | |
| | A67 | Hayasaka et al., "Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma," Hepatology, 24:1058-1062, 1996. | |
| | A68 | Heinrich et al., "Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain," Thrombosis and Haemostasis, 73(3): 374-379, 1995. | |
| | A69 | Hirashima et al., "Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage," Neurochem. Res., 22: 1249-1255, 1997. | |
| | A70 | Hirashima et al., "Cerebrospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage," Stroke, 28:1666-1670, 1997. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|-------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/225,082 | | |
| | | Filing Date | 08/20/2002 | | |
| | | First Named Inventor | Gunars E. Valkirs | | |
| | | Group Art Unit | 1632 | | |
| Sheet | 8 | of | 21 | Examiner Name | |
| | | | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A71 | Hunt et al., "The amino-terminal portion of Pro-brain natriuretic peptide (pro-BNP) circulates in human plasma," Biochem. Biophys. Res. Commun., 214:1175-1183, 1995. | |
| | A72 | Hwang et al., "Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis Circulation, 96:4219-4225, 1997. | |
| | A73 | Isgro et al., "A predictive parameter in patients with brain related complications after cardiac surgery," Eur. J. Cardiothorac. Surg., 11: 640-644, 1997. | |
| | A74 | Jacque et al., "Myelin basic protein in CSF and blood," Arch. Neurol., 39: 557-560, 1982. | |
| | A75 | James, T., "The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding its pathogenesis, clinical course, diagnosis and prognosis," Coron. Artery Dis., 9:291-307, 1998. | |
| | A76 | Jensen et al., "Characterization of human brain S100 protein fraction: amino acid sequence of S100 β , J. Neurochem., 45:700-705, 1985. | |
| | A77 | Johnson et al., "Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques," Arterioscler. Thromb. Vasc. Biol., 18:1707-1715, 1998. | |
| | A78 | Johnsson, "Markers of cerebral ischemia after cardiac surgery," J. Cardiothorac. Vasc. Anesth., 10: 120-126, 1996 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|-----------------------|---|----------------|
| | A79 | Jougasaki et al., "Adrenomedullin: potential in physiology and pathophysiology," Life Sciences, 66(10): 855-872, 2000. | |
| | A80 | Kaneko et al., "Circulating levels of β -chemokines in systemic lupus erythematosus," J. Rheumatol., 26: 568-573, 1999. | |
| | A81 | Kario et al., "'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese," Arterioscler. Thromb. Vasc. Biol., 16: 734-741, 1996. | |
| | A82 | Keyszer et al., "Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers," J.Rheumatol., 26:251-258, 1999. | |
| | A83 | Keyszer et al., "Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity," J.Rheumatol., 57:392-398, 1998. | |
| | A84 | Kim et al., "Involvement of oxidative stress and caspase-3 in cortical infarction after photothrombotic ischemia in mice," Cereb. Blood Flow Metab., 20:1690-1701, 2000. | |
| | A85 | Kim, "Cytokines and adhesion molecules in stroke and related diseases," J.Neurol. Sci., 137:69-78, 1996. | |
| | A86 | Kim et al., "Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist," J.Pharm. Sci., 84:575-580, 1995. | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 10 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |


| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A87 | Kim et al., "Serial measurement of interleukin-6, transforming growth factor- β , and S-100 protein in patients with acute stroke," Stroke, 27:1553-1557, 1996. | |
| | A88 | Koyama et al., "Determination of plasma tissue factor antigen and its clinical significance," Br. J. Haematol., 87:343-347, 1994. | |
| | A89 | Krupinski et al., "Protein kinase expression and activity in the human brain after ischaemic stroke," Acta Neurobiol. Exp. 58:13-21, 1998. | |
| | A90 | Kudo et al., "Clearance and tissue distribution of recombinant human interleukin 1 β in rats," Cancer Res., 50:5751-5755, 1990. | |
| | A91 | Kuwasako et al., "Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension," Ann. Clin. Biochem., 36:622-628, 1999. | |
| | A92 | Landi et al., Hypercoagulability in acute stroke: prognostic significance." Neurol., 37: 1667-1671, 1987. | |
| | A93 | Laskowitz et al., "Serum markers of cerebral ischemia," J.Stroke Cerebrovasc. Dis., 7:234-241, 1998 | |
| | A94 | Latini et al., "Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist," J.Cardiovasc. Pharmacol., 23:1-6, 1994. | |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, respondents are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 11 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |


| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A95 | Lee and Bondy, "Insulin-like growth factors and cerebral ischemia," Ann. N.Y. Acad. Sci., 679:418-422, 1993. | |
| | A96 | Lee et al., "Proteolytic processing of big endothelin-3 by the kell blood group protein," Blood, 94:1440-50, 1999. | |
| | A97 | Legos et al., "Quantitative changes in interleukin proteins following focal stroke in the rat," Neurosci. Letter, 282:189-192, 2000. | |
| | A98 | Lein et al., "Metalloproteinasen (MMP-1, MMP-3) and ihre inhibitoren (TIMP) im blutplasma bei patienten mit prostatakarzinom," Urologe [A], 37:377-381, 1998. | |
| | A99 | Li et al., "The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium <i>in vitro</i> and <i>in vivo</i> ," Mol. Cell. Biochem., 126:61-68, 1993. | |
| | A100 | Liu et al., "Purification and characterization of an interleukin-1 β -converting enzyme family protease that activates cysteine protease P32 (CPP32)," J. Biol. Chem., 271:13371-13376, 1996. | |
| | A101 | Liuzzo et al., "Plasma protein acute-phase response in unstable angina is not induced by ischemic injury," Circulation, 94:2373-2380, 1996. | |
| | A102 | Long et al., "p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes," J. Clin. Invest., 99:2635-2643, 1997. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 12 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A103 | Love et al., "Activation of caspase-3 in permanent and transient brain ischaemia in man," Neuroreport, 11:2495-2499, 2000. | |
| | A104 | Maiuri et al., "Serum and cerebrospinal fluid enzymes in subarachnoid haemorrhage," Neurol. Res., 11:6-8, 1989. | |
| | A105 | Manicourt et al., "Serum levels of collagenase, stromelysin-1, and TIMP-1," Arthritis Rheum., 37:1774-1783, 1994. | |
| | A106 | Martens et al., "Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia," Stroke, 29: 2363-2366, 1998. | |
| | A107 | Mateo and deArtinano, "Highlights of endothelins: A review," Pharm. Res., 36(5): 339-351, 1997. | |
| | A108 | Mathiesen et al., "Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor- α following subarachnoid," J.Neurosurg., 87:215-220, 1997. | |
| | A109 | Matsumori et al., "Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction," J. Mol. Cell. Cardiol., 29:419-423, 1997. | |
| | A110 | McKeating et al., "Leukocyte adhesion molecule profiles and outcome after traumatic brain injury," Acta Neurochir. Suppl., 71:200-202, 1998. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------------|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| Examiner Name | | | |
| Attorney Docket Number | 071949-5404 | | |
| Sheet | 13 | of | 21 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A111 | McKeating et al., "Transcranial cytokine gradients in patients requiring intensive care after acute brain injury," Br. J. Anaesth., 78:520-523, 1997. | |
| | A112 | Missler et al., "S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke," Stroke, 28, 1956-1960, 1997. | |
| | A113 | Miyata et al., "Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Iba," Biol. Chem., 271:9046-9053, 1996. | |
| | A114 | Montalescot et al., "Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease," Circulation, 98:294-299. | |
| | A115 | Moore et al., "Collagenase expression in ovarian cancer cell lines," Gynecol. Oncol., 65:78-82, 1997. | |
| | A116 | Mori et al., "Vasodilator effects of C-type natriuretic peptide on cerebral arterioles in rats," Eur. J. Pharmacol., 320:183-186, 1997. | |
| | A117 | Mowla et al., "Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor," J.Biol. Chem., 276: 12660-12666, 2001. | |
| | A118 | Mun-Bryce and Rosenberg, "Matrix metalloproteinases in cerebrovascular disease," J.Cereb. Blood Flow Metab., 18:1163-1172, 1998. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|-----------------------|--|----------------|
| | A119 | Niebroj-Dobosz et al., "Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes." Folia Neuropathol., 32: 129-137, 1994. | |
| | A120 | Nishiyama et al., "Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes," Jpn. Circ. J., 62:710-712, 1998. | |
| | A121 | Nishizawa et al., "Protein kinase C δ and α are involved in the development of vasospasm after subarachnoid hemorrhage," Eur. J. Pharmacol., 398: 113-119, 2000. | |
| | A122 | Ohtsuka et al., "Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction," Coron. Artery Dis., 10:221-225, 1999. | |
| | A123 | Oltrona et al., "C-Reactive protein elevation and early outcome in patients with unstable angina pectoris," Am. J. Cardiol., 80:1002-1006, 1997. | |
| | A124 | Otsuki et al., "Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients," Diabetes, 46:2096-2101, 1997. | |
| | A125 | Persson et al., "S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system," Stroke, 18:911-918, 1987. | |
| | A126 | Phanithi et al., "Mild hypothermia mitigates post-ischemic neuronal death following focal cerebral ischemia in rat brain: Immunohistochemical study of Fas, caspase-3 and TUNEL," Neuropathol., 20:273-282, 2000. | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|----|------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 15 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A127 | Polin et al., "Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage," J. Neurosurg., 89:559-567, 1998. | |
| | A128 | Prickett et al., "Identification of amino-terminal pro-C-type natriuretic peptide in human plasma," Biochem. Biophys. Res. Commun., 286:513-517, 2001. | |
| | A129 | Quinn et al., "Mapping of antigenic sites in human neuron-specific enolase by expression subcloning," Clin. Chem., 40: 790-795, 1994. | |
| | A130 | Ray et al., "Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy," Cancer Detect. Prev., 22: 293-304, 1998. | |
| | A131 | Rebuzzi et al., "Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris," Am. J. Cardiol., 82:715-719, 1998. | |
| | A132 | Robey et al., "Binding of C-reactive protein to chromatin and nucleosome core particles," J. Biol. Chem., 259:7311-7316, 1984. | |
| | A133 | Romanic et al., "Matrix metalloproteinase expression increases after cerebral focal ischemia in rats," Stroke, 29:1020-1030, 1998. | |
| | A134 | Rosenberg, "Matrix metalloproteinases in brain injury," J. Neurotrauma, 12:833-842, 1995. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 (56 FR 58342), persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 16 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A135 | Rubattu et al., "The gene encoding atrial natriuretic peptide and the risk of human stroke," Circulation, 100:1722-1726, 1999. | |
| | A136 | Rucinski et al., "Clearance of human platelet factor 4 by liver and kidney: its alteration by heparin," Am. J. Ohysiol., 251: H800-H807, 1986. | |
| | A137 | Saraste A., "Morphologic criteria and detection of apoptosis," Herz., 24:189-195, 1999. | |
| | A138 | Schabiltz et al., "Intraventricular brain-derived neurotropic factor reduces infarct size after focal cerebral ischemia in rats," J.Cereb. Blood Flow Metab., 14: 500-506, 1997. | |
| | A139 | Schaller et al., "Elevated levels of head activator in human brain tumors and in serum of patients with brain and other neurally derived tumors," J.Neuro-Oncol., 6:251-258, 1988. | |
| | A140 | Schwab et al., "Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury," Stroke, 28:1744-1748, 1997. | |
| | A141 | Seki et al., "Sustained activation of blood coagulation in patients with cerebral thrombosis," A. J. Hematol., 50: 155-160, 1995. | |
| | A142 | Seki et al., "Plasma levels of thrombomodulin and lipoprotein (a) in patients with cerebral thrombosis," Blood Coagul. Fibrinolysis, 8:391-396, 1997. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 17 of 21

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A143 | Shyu et al., "Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke," J. Neurol., 244:90-93, 1997. | |
| | A144 | Sixma et al., "Von Willebrand factor and the blood vessel wall," Mayo Clin. Proc., 66:628-633, 1991. | |
| | A145 | Skogseid et al., "Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage," Acta Neurochir (Wein), 115: 106-111, 1992. | |
| | A146 | Sorbi et al., "Elevated levels of 92-kd type IV collagenase (Matrix metalloproteinase 9) in giant cell arteritis," Arthritis Rheum., 39:1747-1753, 1996 | |
| | A147 | Steiner et al., "Increased levels of soluble adhesion molecules in Type 2 (Non-insulin dependent) diabetes mellitus are independent of glycaemic control," Thromb. Haemost., 72:979-984, 1994. | |
| | A148 | Stockman et al., "Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopy," Biochemistry, 31:5237-5245, 1992. | |
| | A149 | Stroemer et al., "Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat," J.Cereb. Blood Flow Metab., 17:597-604, 1997. | |
| | A150 | Suga et al., "Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases," Eur. Respir. J., 14:376-382, 1999. | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents; the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet | 18 | of | 21 |
| | | Attorney Docket Number | 071949-5404 |


| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A151 | Sviri et al., "Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage: Clinical and TCD correlations," Stroke, 31:118-122, 2000. | |
| | A152 | Switalska et al., "Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and β -thromboglobulin antigen secretion and clearance from the circulation," J. Lab. Clin. Med., 106: 690-700, 1985. | |
| | A153 | Takahashi et al., "Tissue factor in plasma of patients with disseminated intravascular coagulation," Am. J. Hematol., 46:333-337, 1994. | |
| | A154 | Takano et al., "Markers of a hypercoagulable state following acute ischemic stroke," Stroke, 23:194-198, 1992. | |
| | A155 | Tateyama et al., "Concentrations and molecular forms of human brain natriuretic peptide in plasma," Biochem. Biophys. Res. Commun., 185:760-7, 1992. | |
| | A156 | Teitz Textbook of Clinical Chemistry, 2 nd edition, Carl Burtis and Edward Ashwood eds. Philadelphia: W.B.Saunders and Company, p. 496. | |
| | A157 | Thomas et al., "Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury," Acta Neurochir. Suppl., 28: 93-95, 1979. | |
| | A158 | Tohgi et al., "Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism," Stroke, 21: 1663-1667, 1990. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/225,082 |
| Filing Date | 08/20/2002 |
| First Named Inventor | Gunars E. Valkirs |
| Group Art Unit | 1632 |
| Examiner Name | |
| Attorney Docket Number | 071949-5404 |

Sheet 19 of 21

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A159 | Tomida et al., "Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage," Stroke, 29:1584-1587, 1998. | |
| | A160 | Tousoulis et al., "Von Willebrand factor in patients evolving Q-wave versus non-Q-wave acute myocardial infarction," Int. J. Cardiol., 56:259-262, 1996. | |
| | A161 | Trotter et al., "Immunoreactive myelin proteolipid protein-like activity in cerebrospinal fluid and serum of neurologically impaired patients," Ann. Neurol., 14: 554-558, 1983. | |
| | A162 | Uchiyama et al., "Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke," Semin. Thromb. Hemost., 23: 535-541, 1997. | |
| | A163 | Usui et al., "β-enolase in blood plasma during open heart surgery," J.Neurol., 123:134-139, 1994. | |
| | A164 | Wada et al., "Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries," Am. J. Hematol., 58:189-194, 1998. | |
| | A165 | Wang et al., "Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex," Stroke, 26:661-665, 1995. | |
| | A166 | Wijdicks et al., "Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage," J. Neurosurg., 87:275-280, 1997. | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-5404 |
| Sheet | 20 | of | 21 |


| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A167 | Wilkins et al., "The natriuretic-peptide family," Lancet, 349:1307-1310, 1997. | |
| | A168 | Winnikes et al., "Head activator as a potential serum marker for brain tumor analysis," Eur. J. Cancer, 28:421-424, 1992. | |
| | A169 | Woertgen et al., "Comparison of serial S-100 and NSE serum measurements after severe head injury," Acta Neurochir (Wien), 139: 1161-1165, 1997. | |
| | A170 | Yamagami et al., "Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats," J. Leukoc. Biol., 65:744-749, 1999. | |
| | A171 | Yamazaki et al., "Alterations of haemostatic markers in various subtypes and phases of stroke," Blood Coagul., Fibrinolysis, 4:707-712, 1993. | |
| | A172 | Yang et al., "Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury," Brain Res. 751: 181-188, 1997. | |
| | A173 | Yap et al., "Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi," Br. J. Pharmacol., 129:170-7, 2000. | |
| | A174 | Yazdani et al., "Percutaneous interventions after the hemostatic profile of patients with unstable versus stable angina," J. Am. Coll. Cardiol., 30:1284-1287, 1997. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/225,082 |
| | | Filing Date | 08/20/2002 |
| | | First Named Inventor | Gunars E. Valkirs |
| | | Group Art Unit | 1632 |
| | | Examiner Name | |
| Sheet 21 of 21 | Attorney Docket Number | 071949-5404 | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | A175 | Yoneda et al., "Identification of a novel adenylate kinase system in the brain: Cloning of the fourth adenylate kinase," Mol. Brain Res., 62: 187-195, 1998. | |
| | A176 | Yoshimura et al., "Human monocyte chemoattractant protein-1 (MCP-1)," FEBS Lett., 244:487-493, 1989. | |
| | A177 | Yoshitomi et al., "Plasma levels of adrenomedullin in patients with acute myocardial infarction," Clin. Sci. 94:135-9, 1998 | |
| | A178 | Zucker et al., "Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity," J.Rheumatol., 26:78-80, 1999. | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.